About nacnkcell
This author has yet to write their bio.
Meanwhile lets just say that we are proud nacnkcell contributed a whooping 14 entries.
Entries by
Anthony Nolan Cell & Gene Therapy Services and ONK Therapeutics Announce Collaboration
22/02/2021 in News, Uncategorised /by nacnkcellAnthony Nolan Cell & Gene Therapy Services will provide umbilical cord blood and cord-derived NK cells to facilitate the development of ONK Therapeutics’ next-generation dual-targeted NK cell therapies Collaboration supports a common mission to improve the lives of patients with hematological malignancies and solid tumors London, UK and Galway, Ireland, and San Diego, USA 22 […]
ONK Therapeutics Appoints Mary Reilly as Chief Operating Officer
18/01/2021 in News /by nacnkcellMary Reilly joins as COO, to lead the company’s international operations and drive growth ambitions to transition from a pre-clinical to a clinical-stage company 30 years’ experience in all aspects of global drug development and company operations Prior experience as COO at Opsona Therapeuticsas well as at BioInvent International, Neuramedy, Elan Pharmaceuticals, and Taro Pharmaceuticals […]
ONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman
14/01/2021 in News /by nacnkcellUS-based Hugh O’Dowd joins the Board as independent Non-executive Chairman Brings significant experience in commercialization of oncology drugs Led Neon Therapeutics, Inc. for four years through to its acquisition by BioNTech SE Twenty years of big pharma experience gained at Novartis, including as CCO of Novartis Oncology Galway, Ireland and San Diego, USA, 14 January […]
ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline
17/12/2020 in News /by nacnkcellThree new exclusive option license agreements expand the depth and breadth of ONK’s pre-clinical pipeline A humanized scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth pre-clinical program, ONKT104, for the treatment of acute myeloid leukemia (AML) A humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitope licensed from Glycotope GmbH, strengthens pre-clinical program […]
ONK Therapeutics Opens US R&D Operations and Appoints Head of R&D, USA
12/11/2020 in News /by nacnkcellONK opens US operations and becomes a resident of Johnson & Johnson Innovation JLABS @ San Diego Rohit Duggal Ph.D. appointed as Head of R&D, USA ONK Therapeutics, Inc. formed, to facilitate the expansion of operations in the USA, alongside its growing hub in Galway, Ireland Galway, Ireland and San Diego, USA, 12 November 2020 […]
European Cancer Deals Increasingly Focus on Natural Killer Cells
30/10/2020 in In the news /by nacnkcellLabiotech – View full story
Mulligan backs ONK Therapeutics in $8m funding
19/10/2020 in In the news /by nacnkcellThe Irish Times – View full story
Kite’s former EU chief Nowers joins NK cell startup ONK as CEO
19/10/2020 in In the news /by nacnkcellFierce Biotech – View full story
Unit 1 an Coirneal
Pier Road, Barna
Co. Galway H91 V6KV